Therapeutic Solutions International, Inc., a company based in the United States, has been actively engaged in the development, production, and marketing of treatments targeting neurological, sleep, and temporomandibular disorders. As of March 31, 2026, the company is listed on the OTC Bulletin Board, trading under the currency of USD. The close price of the company’s stock on March 29, 2026, was recorded at $0.0001, which also represents the 52-week low for the company, observed on the same date. The 52-week high was previously noted at $0.0003 on April 22, 2025.
The market capitalization of Therapeutic Solutions International, Inc. stands at $7,050, reflecting its current valuation in the market. This valuation is indicative of the company’s size and financial health within its sector. The company’s focus on specialized treatments for neurological and sleep disorders, as well as temporomandibular disorders, positions it within a niche market that addresses significant health concerns.
The company’s strategic emphasis on these specific medical areas highlights its commitment to addressing unmet medical needs. By concentrating on neurological and sleep disorders, Therapeutic Solutions International, Inc. aims to provide innovative solutions that can improve the quality of life for patients suffering from these conditions. Similarly, its efforts in treating temporomandibular disorders underscore its dedication to enhancing oral health and overall well-being.
Despite the challenges faced by many companies in the biotechnology and pharmaceutical sectors, Therapeutic Solutions International, Inc. continues to pursue its mission of developing effective treatments. The company’s activities in research and development are crucial for advancing its product pipeline and achieving long-term growth. As it navigates the competitive landscape, the company’s ability to innovate and bring new treatments to market will be key to its success.
In summary, Therapeutic Solutions International, Inc. remains focused on its core mission of developing and marketing treatments for neurological, sleep, and temporomandibular disorders. With a market capitalization of $7,050 and a current stock price of $0.0001, the company continues to operate within a specialized segment of the healthcare industry, aiming to address critical health issues through its innovative product offerings.
